Target and Technology
SEA-CD40 uses our novel sugar-engineered antibody (SEA) technology and is directed against the protein CD40. CD40 is a promising target in cancer therapy. It acts as an immune-activating receptor capable of driving an antitumor response. CD40 is expressed by a wide range of normal cells, including immune, blood-forming stem, blood vessel and skin cells, as well as cancer cells.
SEA-CD40 is an agonistic antibody designed to induce and enhance the body’s own antitumor response. It can also directly kill CD40-expressing cancer cells through antibody-dependent cellular cytotoxicity, providing a distinctive therapeutic approach that is complementary to our ADC technology.
Clinical Development Status
- Phase 1 trial evaluating the safety and activity of the SEA-CD40 immunotherapy in patients with unresectable solid tumors and some hematologic cancers
Proposed Mechanism of Action
SEA-CD40 is an investigational agent, and its safety and efficacy have not yet been established.